Prelude Therapeutics PRLD Balance Sheet (2019-2026)

NASDAQ PRLD
$5.46 +0.21 (+4.00%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Prelude Therapeutics Quarterly Balance Sheet

Periods 28 quarters
Latest Jun 2026

Prelude Therapeutics reported total assets of $189.36M and total liabilities of $55.63M for the quarter ended Jun 2026, up 64.8% year over year. This balance sheet covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Assets
Current Assets
Cash & EquivalentsCash & Equiv.
61.42M35.87M55.68M54.75M56.07M34.65M22.25M30.49M19.94M29.34M28.75M31.87M15.18M16.52M44.31M29.80M58.20M38.49M84.80M155.20M
Short-term InvestmentsInvestments (Current)
259.44M259.40M214.56M195.60M172.02M171.12M154.05M228.54M214.61M207.64M177.22M152.02M142.49M121.14M58.80M47.46M7.42M67.96M59.80M125.43M
Cash & Current Investments
320.87M295.28M270.23M250.35M228.09M205.77M176.30M259.03M234.55M236.98M205.97M183.89M157.67M137.66M103.12M77.26M65.62M106.45M144.60M280.63M
Prepaid Assets
5.03M3.88M3.78M2.32M2.85M2.65M3.01M5.22M4.41M2.65M3.44M2.87M2.76M2.28M3.33M3.66M3.37M2.48M3.04M3.14M
Current Assets
325.90M295.12M269.97M248.62M226.89M204.38M175.26M260.21M234.92M235.59M205.37M182.71M156.39M135.90M102.40M76.88M58.33M105.69M84.59M154.90M
Non-Current Assets
Property, Plant & Equipment (Net)PP&E (Net)
3.21M3.93M4.12M4.29M5.11M4.91M5.37M6.08M6.62M7.33M7.29M7.55M7.20M6.77M6.39M5.96M5.53M5.11M4.72M4.40M
Other Non-Current Assets
4.04M4.04M4.04M4.93M5.38M12.28M9.36M12.47M4.04M4.04M4.04M4.04M4.04M4.04M4.04M3.23M3.23M3.23M3.40M
Non-Current Assets
5.32M9.98M10.70M10.43M15.43M16.12M23.06M20.40M23.59M42.08M41.74M41.58M40.83M39.62M38.86M38.04M36.42M35.62M35.05M34.47M
Assets
331.22M305.10M280.67M259.06M242.33M220.50M198.32M280.61M258.51M277.67M247.11M224.29M197.22M175.51M141.26M114.92M94.75M141.31M119.64M189.36M
Liabilities
Current Liabilities
Accounts Payables
11.06M7.84M7.39M6.27M10.25M6.78M7.08M5.58M5.17M4.58M5.31M6.17M5.92M7.73M5.83M4.96M2.53M3.98M2.07M2.03M
Payables
11.06M7.84M7.39M6.27M10.25M6.78M7.08M5.58M5.17M4.58M5.31M6.17M5.92M7.73M5.83M4.96M2.53M3.98M2.07M2.03M
Accumulated Expenses
6.76M9.62M6.82M7.72M9.92M13.09M11.19M8.67M11.25M15.77M10.15M11.43M13.58M15.21M11.30M13.23M12.93M12.53M5.94M7.98M
Other Accumulated Expenses
0.57M0.09M0.35M0.29M0.17M0.52M0.89M0.81M0.82M0.94M0.80M0.46M0.80M0.77M0.70M0.86M0.96M0.96M0.91M0.63M
Current Leases
1.84M1.74M1.86M1.82M1.39M1.83M1.39M0.94M0.47M1.48M2.19M2.23M2.37M2.49M2.60M2.71M2.73M2.74M2.76M2.78M
Current Deferred Revenue
3.00M33.73M30.95M25.25M
Total Current Liabilities
19.66M19.20M16.07M15.81M21.56M21.70M19.66M15.19M16.89M21.83M17.64M23.34M22.22M25.64M19.79M20.91M18.19M52.99M41.72M38.04M
Non-Current Liabilities
Non-Current Deffered Revenue
1.80M
Preferred Stock Liabilities
Operating Leases
0.31M0.39M16.89M15.45M18.20M18.14M15.32M15.27M15.21M15.13M15.04M14.96M14.87M
Other Non-Current Liabilities
2.40M2.40M3.36M3.36M3.36M3.36M3.36M3.34M3.28M3.21M3.15M3.09M3.03M2.97M2.90M2.84M2.78M2.72M
Total Non-Current Liabilities
19.20M16.46M15.81M21.56M21.70M19.66M15.19M16.89M37.24M33.09M38.80M37.64M40.97M35.05M36.11M33.32M69.84M56.68M52.91M
Total Liabilities
19.98M19.20M18.86M18.21M24.92M25.06M23.02M18.55M20.25M40.58M36.37M42.02M40.79M44.06M38.08M39.08M36.22M72.68M59.46M55.63M
Shareholder's Equity
Common Equity
311.24M285.90M261.81M240.84M217.41M195.44M175.30M262.06M238.26M237.09M210.73M182.28M156.43M131.46M103.18M75.84M58.53M68.64M60.18M133.73M
Liabilities and Shareholders Equity
331.22M305.10M280.67M259.06M242.33M220.50M198.32M280.61M258.51M277.67M247.11M224.29M197.22M175.51M141.26M114.92M94.75M141.31M119.64M189.36M
Retained Earnings
-186.30M-219.12M-248.60M-276.00M-305.92M-334.56M-362.30M-392.71M-423.31M-456.39M-487.82M-522.60M-554.83M-583.56M-615.65M-646.90M-666.60M-683.06M-693.45M-707.40M
Treasury Shares